Skip to main content

Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

November 18, 2020
View a 4-part CME video series on assessing for and treating tardive dyskinesia during the COVID-19 pandemic.
October 01, 2020
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
October 01, 2020
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
October 01, 2020
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 
July 26, 2020
A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?
July 25, 2020
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych Congress Elevate.
July 21, 2020
A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
July 20, 2020
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, is educating clinicians on the latest research and strategies for treating tardive dyskinesia during the 2020 Psych Congress Regionals meetings. He shares some of his guidance here.
July 15, 2020
Which of the following is a risk factor for tardive dyskinesia (TD): age, diagnosis of schizophrenia, comorbid bipolar and related disorders, history of extrapyramidal symptoms, or all of these?
July 10, 2020
    In order to be diagnosed with tardive dyskinesia (TD), a patient must experience involuntary choreifo
Back to Top